Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
April 26th, 2017
This report describes a bioengineering method to design and construct novel Artificial Splicing Factors (ASFs) that specifically modulate the splicing of target genes in mammalian cells. This method can be further expanded to engineer various artificial factors to manipulate other aspects of RNA metabolism.
Overview
This report details a bioengineering method for designing Artificial Splicing Factors (ASFs) that modulate gene splicing in mammalian cells. This flexible technique can be adapted to manipulate various aspects of RNA metabolism.
Key Study Components
Area of Science
- Bioengineering
- RNA processing
- Gene regulation
Background
- Alternative splicing is crucial for gene expression regulation.
- Misregulation of splicing is implicated in diseases like cancer.
- Current methods for studying splicing are limited.
- Engineering ASFs can provide new insights into RNA metabolism.
Purpose of Study
- To develop ASFs that can specifically manipulate alternative splicing.
- To explore the regulation of splicing in cancer cells.
- To create tools for studying RNA processing dynamics.
Methods Used
- Designing artificial splicing factors using wild-type PUF DNA as a template.
- Customizing PUF domain scaffolds for specific gene targets.
- Demonstrating the procedure with laboratory associates.
- Assessing the effects of ASFs on splicing outcomes.
Main Results
- Successful engineering of ASFs that can promote or inhibit splicing.
- Demonstrated flexibility in targeting various genes.
- Provided insights into the regulation of alternative splicing.
- Potential applications in understanding RNA metabolism in diseases.
Conclusions
- The method offers a novel approach to study RNA splicing.
- ASFs can be tailored for specific research needs.
- This technique may advance our understanding of RNA-related diseases.
Frequently Asked Questions
Executive Industry Relevance
Engineering artificial splicing factors enables precise interrogation of RNA processing mechanisms, supporting target validation in disease-relevant systems. This approach provides mechanistic de-risking by linking specific splicing events to functional outcomes, improving predictive confidence in early discovery. The method’s flexibility allows adaptation across multiple genes and splicing types, enhancing translational biomarker discovery and preclinical model relevance.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables hypothesis testing of splicing regulation in disease contexts such as cancer misregulation.
- Operational Value: Provides a programmable scaffold for generating RNA-binding proteins with defined specificity.
- Strategic Value: Supports target de-risking by modulating alternative splicing to assess isoform-specific functions.
Screening & Assay Development
- Scientific Value: Facilitates quantitative measurement of splicing changes via reporter assays and densitometry.
- Operational Value: Enables standardized assessment of factor activity using splicing reporters in HEK-293T cells.
- Strategic Value: Supports assay reproducibility for screening compound effects on RNA processing.
Translational & Preclinical Research
- Scientific Value: Links splicing modulation to phenotypic outcomes such as apoptosis in human cells.
- Operational Value: Uses immunofluorescence and RNA extraction to validate nuclear localization and functional impact.
- Strategic Value: Enables phenotypic screening to connect splicing changes to cellular responses.
Pipeline & Workflow Integration
The method integrates into early discovery workflows by enabling target-specific RNA manipulation prior to lead identification and preclinical validation.
- Discovery Biology: Supports mechanistic interrogation of splicing regulation in disease-relevant systems.
- Screening: Enables quantitative, reproducible assessment of splicing modulation using reporter-based assays.
- Analytics: Generates measurable outputs such as isoform ratios and apoptotic phenotypes for data-driven decisions.
- Translational Research: Connects splicing changes to functional outcomes in human cells, supporting biomarker alignment.
- Enterprise Reuse: The PUF scaffold platform can be reused across multiple targets, reducing redevelopment effort.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in RNA processing by enabling specific, tunable splicing modulation.
- Operational Value: Standardized workflow for constructing and testing engineered splicing factors in mammalian cells.
- Strategic Value: Improves go/no-go decisions by providing early functional validation of splicing targets.
- Portfolio Impact: Enables risk-adjusted prioritization of targets based on splicing-dependent phenotypes.
Implementation Considerations
- Requires expertise in molecular cloning, PCR-based scaffold engineering, and mammalian cell transfection.
- Dependent on access to thermal cyclers, electrophoresis systems, fluorescence scanners, and microscopes.
- Necessitates standardization of reporter plasmids and transfection protocols across teams.
- Adaptation to different cell types or primary tissues may require optimization of transfection and assay conditions.
- Practical limitations include the time required for PUF domain construction and validation of specificity for each target.
Biopharma FAQs
Chapters in this video
0:05
Title
0:51
Construction of the PUF RNA-binding Domain Scaffold with Customized RNA Binding Specificity by Overlapping PCR
2:05
Transfection of Engineered Splicing Factors (ESFs) for Modulation of Exon Inclusion and Alternative Splice-site Use
6:24
Modulation of Endogenous Bcl-x Splicing and Apoptosis by ESFs
8:23
Results: Subcellular Localization of ESFs in Transfected HeLa Cells
9:30
Conclusion
3:43
Cell Harvest and Identification of Spliced Isoforms
